Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0575u-hepatotrack-liver-allograft-rejection-mirna-rtpcr
    Ask Trek AI about this page

    CPT 0575U: HepatoTrack™ miRNA Assay for Liver Allograft Rejection

    CPT code 0575U is a Proprietary Laboratory Analyses (PLA) code for the HepatoTrack™ assay from LuminoDx Inc., a blood-based RT–PCR test that measures expression of four microRNAs (miR-122, miR-885, miR-23a and a spike-in control) to generate a risk score for liver allograft rejection; the service is a molecular diagnostic laboratory test (proprietary PLA molecular assay) typically performed in a clinical laboratory or reference lab with blood draw as the site of specimen collection.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0575U policy alerts

    Get alerted when payer policies referencing 0575U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 54-year-old male liver transplant recipient presents for routine post-transplant surveillance with recent abnormalities in liver function tests and intermittent low-grade fevers. The transplant hepatologist orders HepatoTrack™ (LuminoDx Laboratory) to assess risk of allograft rejection by measuring expression of four microRNAs in peripheral blood. A phlebotomy appointment is scheduled at an outpatient infusion center or clinical laboratory. A whole-blood sample is collected into the tube specified by the manufacturer, labeled with patient and order identifiers, and shipped to LuminoDx Laboratory under required temperature and chain-of-custody conditions. The laboratory performs reverse transcription polymerase chain reaction (RT–PCR) measuring miR-122, miR-885, miR-23a (housekeeping gene), and a spike-in control, calculates a composite risk score, and reports a result to the ordering transplant hepatologist and transplant surgery team. Typical sites of service include outpatient hospital laboratories, independent commercial reference laboratories, and hospital outpatient infusion or transplant clinics. Common clinical use cases include surveillance for subclinical rejection, evaluation of unexplained LFT elevations, and monitoring during immunosuppression adjustment.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0575UHepatoTrack™ microRNA RT–PCR assay measuring miR-122, miR-885, miR-23a and spike-in control to generate a liver allograft rejection risk score (Proprietary Laboratory Analyses)This is the specific proprietary test performed by LuminoDx Laboratory; primary billed PLA code for the assay.

    36415 | Collection of venous blood by venipuncture | Often performed immediately prior to sending specimen for the HepatoTrack™ assay; billed by outpatient lab or phlebotomy service.

    99000 | Handling and/or conveyance of specimen for transfer from a site other than the performing laboratory to the laboratory performing the test | Use when specimen is collected at a clinic or hospital and transported to the reference laboratory performing the proprietary assay.

    80307 | Drug assay, definitive; testing by mass spectrometry or similar (example molecular or specialized assays) | Not directly the same methodology but represents advanced molecular/definitive laboratory services commonly billed alongside specialized assays when additional molecular testing is performed; included as a related advanced-laboratory code in workflows.

    83890 | Molecular pathology procedure other than CPT codes 83900-83914; each nucleic acid (DNA or RNA) probe or target | Use in institutional coding environments for molecular test components if local payor or facility mapping requires crosswalks to molecular pathology series alongside PLA codes.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0000X
    2080P0208X
    207L00000X
    207SG0203X
    282NC2000X
    310500000X
    163WL0100X
    225500000X

    Related ICD-10-CM Codes

    30 rows

    ICD-10-CM CodeDescription
    B18.1Chronic viral hepatitis B without delta-agent
    B18.2Chronic viral hepatitis C
    C22.0Liver cell carcinoma
    C22.9Malignant neoplasm of liver, not specified as primary or secondary
    E10.65Type 1 diabetes mellitus with hyperglycemia
    E11.65Type 2 diabetes mellitus with hyperglycemia
    E78.5Hyperlipidemia, unspecified
    I85.00Esophageal varices without bleeding
    I85.01Esophageal varices with bleeding
    K72.90Hepatic failure, unspecified without coma

    Showing 1–10 of 30

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.